Caryn Gordon Mcdowell Sells 11,348 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) insider Caryn Gordon Mcdowell sold 11,348 shares of Cytokinetics, stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $12.47, for a total value of $141,509.56. Following the transaction, the insider now owns 21,570 shares of the company’s stock, valued at approximately $268,977.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Cytokinetics, Incorporated (NASDAQ CYTK) traded up 1.25% during trading on Friday, hitting $12.15. The stock had a trading volume of 629,882 shares. The firm’s market cap is $652.04 million. Cytokinetics, Incorporated has a 52-week low of $8.51 and a 52-week high of $17.20. The stock has a 50 day moving average of $13.43 and a 200 day moving average of $13.03.

Cytokinetics, (NASDAQ:CYTK) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.03. The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $5.28 million. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. On average, equities analysts anticipate that Cytokinetics, Incorporated will post ($2.08) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thestockobserver.com/2017/08/12/caryn-gordon-mcdowell-sells-11348-shares-of-cytokinetics-incorporated-nasdaqcytk-stock.html.

A number of equities analysts have issued reports on CYTK shares. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Cytokinetics, in a research note on Tuesday, April 25th. Zacks Investment Research downgraded Cytokinetics, from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 4th. Cowen and Company reiterated an “outperform” rating and set a $19.00 price target (up previously from $17.00) on shares of Cytokinetics, in a research note on Saturday, April 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics, in a research note on Friday, May 19th. Finally, ValuEngine upgraded Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $21.30.

Several large investors have recently made changes to their positions in CYTK. Alambic Investment Management L.P. increased its stake in shares of Cytokinetics, by 115.9% in the first quarter. Alambic Investment Management L.P. now owns 28,500 shares of the biopharmaceutical company’s stock valued at $366,000 after buying an additional 15,300 shares during the period. Norges Bank purchased a new stake in shares of Cytokinetics, during the fourth quarter valued at $976,000. Piermont Capital Management Inc. purchased a new stake in shares of Cytokinetics, during the first quarter valued at $612,000. Capital Fund Management S.A. purchased a new stake in shares of Cytokinetics, during the first quarter valued at $213,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Cytokinetics, during the second quarter valued at $436,000. 59.76% of the stock is owned by institutional investors.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply